Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
UnicoCell Biomed Co's Other Operating Expense for the
three
months ended in Mar. 2026 was NT$-0.00 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was NT$-0.00 Mil.
UnicoCell Biomed Co's quarterly Other Operating Expense
increased
from Sep. 2025 (NT$-0.00 Mil) to Dec. 2025 (NT$0.00 Mil) but then
declined
from Dec. 2025 (NT$0.00 Mil) to Mar. 2026 (NT$-0.00 Mil).
UnicoCell Biomed Co's annual Other Operating Expense
increased
from Dec. 2023 (NT$-0.00 Mil) to Dec. 2024 (NT$0.00 Mil) but then
stayed the same
from Dec. 2024 (NT$0.00 Mil) to Dec. 2025 (NT$0.00 Mil).
UnicoCell Biomed Co Other Operating Expense Related Terms
UnicoCell Biomed Co Other Operating Expense Historical Data
* Premium members only.
The historical data trend for UnicoCell Biomed Co's Other Operating Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of NT$-0.00 Mil mean?
UnicoCell Biomed Co (TPE:6794) has a Other Operating Expense of NT$-0.00 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on UnicoCell Biomed Co and its competitors.
Is UnicoCell Biomed Co's Other Operating Expense too high?
UnicoCell Biomed Co's current Other Operating Expense is NT$-0.00 Mil. Overall, UnicoCell Biomed Co has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Other Operating Expense compare to VRTX and REGN?
UnicoCell Biomed Co's Other Operating Expense of NT$-0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current Other Operating Expense is NT$-0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Fairly Valued. The stock's GF Value™ is NT$81.18, compared to a current price of NT$74.40 — trading 8.4% below its estimated fair value. The current Other Operating Expense is NT$-0.00 Mil. UnicoCell Biomed Co's overall GF Score™ is 82/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Other Operating Expense is NT$-0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?
Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued.
The current stock price of NT$74.40 is trading 8.4% below its estimated GF Value™ of NT$81.18.
GuruFocus considers UnicoCell Biomed Co to be Fairly Valued.
Key valuation signals for TPE:6794:
Other Operating Expense: NT$-0.00 Mil
GF Value™: NT$81.18 vs. price of NT$74.40 (8.4% below fair value)
No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
82GF Score
Get the complete analysis for TPE:6794
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6794 has been successfully added to your 
